Astellas Pharma US, Inc.

527 articles with Astellas Pharma US, Inc.

• Astellas Partners With The Quebec Urological Association Foundation To Advance Urology Research

  11/11/2016

• Astellas Establishes Patient Experience Organization In The Americas

  11/2/2016

• Little-Known Ganymed Grabs a $1.4 Billion Buyout Deal From Astellas

  10/31/2016

• Astellas Release: FDA Approves Supplemental New Drug Application For XTANDI (Enzalutamide) Capsules In Advanced Prostate Cancer

  10/21/2016

• World Anti-Doping Agency And Astellas Announce Global Initiative To Prevent Misuse And Abuse Of Medicines For Doping In Sports

  10/14/2016

• Chromocell And Astellas Announce FDA Fast Track Designation And First Subject Dosing With Lead Candidate CC8464/ASP1807 For The Management Of Neuropathic Pain Associated With iSFN

  10/13/2016

• Seattle Genetics And Agensys, Inc., An Affiliate Of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) And ASG-15ME Phase 1 Data In Metastatic Urothelial Cancer At 2016 ESMO Congress

  10/7/2016

• Astellas Expands Leadership In Oncology Clinical Development

  10/5/2016

• Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas

  9/29/2016

• Working Mother Magazine Names Astellas Among 100 Best Companies in the US Across All Industries

  9/28/2016

• Astellas, Vical 's Experimental Herpes Vaccine Flunks Mid-Stage Test

  9/19/2016

• Courtagen Collaborates With Astellas For Mitochondrial Disorder Drug Development

  9/15/2016

• Astellas And World Transplant Games Federation Announce Launch Of Fit For Life! To Promote Physical Activity In Transplant Recipients Worldwide

  8/19/2016

• Proteostasis Achieves Preclinical Milestone In Astellas Collaboration

  8/9/2016

• Astellas' Tyler Marciniak Named To PRWeek's 40 Under 40

  8/5/2016

• Avara Picks Up Astellas' U.S. Manufacturing Facility

  8/4/2016

• Astellas Reports First Quarter Financial Results Of FY2016

  7/29/2016

• Astellas Launches DigiTx Partners, A Digital Health Investment Company In Partnership With MPM Capital

  7/29/2016

• Comeback Kid Cytokinetics Pockets $95 Million Upfront in R&D Deal With Astellas, Needs Results for More

  7/27/2016

• Astellas And FibroGen Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan

  7/26/2016